Randomized, placebo-controlled trial of the anti-tumor necrosis factor antibody fragment afelimomab in hyperinflammatory response during severe sepsis: The RAMSES Study

Konrad Reinhart, Martin Kaul, Klaus Tschaikowsky et al.|Critical Care Medicine|2001

Cited by 261